Editas Medicine, Inc. Debt Disclosure
| December 31, 2025 | |||||
| Liability for the sale of future revenues, net as of December 31, 2024 | $ | 57,434 | |||
| Payments for sale of future revenues | (5,000) | ||||
| Non-cash interest expense associated with sale of future revenues | 5,781 | ||||
| Amortization of issuance costs | 390 | ||||
| Liability for the sale of future revenues, net as of December 31, 2025 | $ | 58,605 | |||
Want the next Editas Medicine, Inc. debt disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Editas Medicine, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 9, 2026 | Showing above |
| 2024 | Mar 5, 2025 | |
About Debt Disclosures
Debt disclosures detail a company's borrowing structure — the types of instruments, interest rates, maturity schedule, and covenant restrictions that define its financial obligations and flexibility. This section is essential for assessing refinancing risk, interest rate exposure, and the margin of safety against financial distress.
Key signals: the maturity schedule reveals concentration risk — large maturities within 1-2 years during tight credit markets can force dilutive refinancing or asset sales. Compare the fair value of debt against carrying amount to gauge whether the market views the company's credit risk differently than the balance sheet suggests. Watch covenant compliance disclosures for tightening cushions, especially leverage and interest coverage ratios. Variable-rate debt exposure quantifies sensitivity to interest rate changes. Secured versus unsecured mix affects recovery rates and future borrowing capacity. Compare net debt-to-EBITDA against industry peers and covenant limits to assess financial health.